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Abstract
Background: During 2009- 2010, pandemic influenza A (H1N1) pdm09 virus (pH1N1) 
infections in England occurred in two epidemic waves. Reasons for a reported in-
crease in case- severity during the second wave are unclear.
Methods: We analysed hospital- based surveillance for patients with pH1N1 infec-
tions in England during 2009- 2010 and linked national data sets to estimate ethnicity, 
socio- economic status and death within 28 days of admission. We used multivariable 
logistic regression to assess whether changes in demographic, clinical and manage-
ment characteristics of patients could explain an increase in ICU admission or death, 
and accounted for missing values using multiple imputation.
Results: During the first wave, 54/960 (6%) hospitalised patients required intensive 
care and 21/960 (2%) died; during the second wave 143/1420 (10%) required inten-
sive care and 55/1420 (4%) died. In a multivariable model, during the second wave 
patients were less likely to be from an ethnic minority (OR 0.33, 95% CI 0.26- 0.42), 
have an elevated deprivation score (OR 0.75, 95% CI 0.68- 0.83), have known comor-
bidity (OR 0.78, 95% CI 0.63- 0.97) or receive antiviral therapy ≤2 days before onset 
(OR 0.72, 95% CI 0.56- 0.92). Increased case- severity during the second wave was not 
explained by changes in demographic, clinical or management characteristics.
Conclusions: Monitoring changes in patient characteristics could help target inter-
ventions during multiple waves of COVID- 19 or a future influenza pandemic. To 
understand and respond to changes in case- severity, surveillance is needed that in-
cludes additional factors such as admission thresholds and seasonal coinfections.
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1  | BACKGROUND
During 2009- 2010, influenza A (H1N1)pdm09 virus (pH1N1) infec-
tions occurred in two distinct epidemic waves in several countries, 
including in England1- 3 and in the United States.4- 6 Infections with 
pH1N1 leading to hospital admissions in England were reported to 
be more severe during the second wave than during the first wave,3,7 
in contrast to the United States4,5 and Canada.8 A Bayesian analysis 
from available data estimated an increase in overall case- severity in 
England,9 consistent with a sentinel surveillance study that noted 
patients hospitalised during the second wave were nearly twice as 
likely to be admitted to an intensive care unit (ICU) or to die follow-
ing infection.3
However, it is unclear whether shifts in patient characteristics or 
health interventions between epidemic waves could have explained 
the reported increase in clinical severity. Sentinel surveillance from 
England indicated that patients during the second wave in England 
were generally older3; similar shifts were reported in the United 
States and Canada.5,8 There was also a greater geographic dispersal 
of cases during the second wave, while fewer cases were reported 
from ethnic minority groups.3,5 It is possible that this reflected dif-
ferences in the socio- economic status.10- 12
Changes in health interventions might also have explained an 
increase in case- severity. In England, there was a decline in the pro-
portion of patients with pH1N1 receiving timely antiviral therapy 
during the second wave,2,3 in contrast to the United States.4,5 A ten-
dency to admit only patients with more severe infections during the 
second wave might also explain an increased case- severity among 
hospitalised patients.
Understanding whether increased case- severity can be explained 
by changes in other patient characteristics could inform responses 
to COVID- 19 and to future influenza pandemics. We analysed na-
tional surveillance data of cases hospitalised during the 2009/2010 
pH1N1 pandemic to determine whether reported increased severity 
of infections among hospitalised patients during the second wave 
could be explained by changes in reported patient characteristics or 
health interventions between waves.
2  | METHODS
Surveillance data were collected for patients with laboratory- 
confirmed influenza A (H1N1)pdm09 virus infection admitted 
between 27th May 2009 and 5th January 2010 to 129/166 partici-
pating NHS Trusts in England. Case information was collected using 
a standard form under the joint direction of the Health Protection 
Agency (HPA) and the Chief Medical Officer, as part of enhanced 
pandemic surveillance using methods reported previously.1
Case- severity was defined as the probability that a hospitalised 
patient was admitted to ICU or died. Information on potential ex-
planatory factors was gathered for case demographics (region, age, 
gender, ethnicity, underlying risk factors), and interventions (time to 
hospital admission, use of antivirals).
Further data sets were used to assess socio- economic status, 
ethnicity, and mortality up to 28 days after admission. We used 
the Index of Multiple Deprivation (IMD) score to estimate socio- 
economic status based on place of residence, with a higher score 
indicating more deprivation. This score is compiled by the Office of 
National Statistics (ONS), by lower super output areas (LSOAs) of 
approximately 300 residents which allow matching by a patient's 
residential postcode.13 We used quartiles of England LSOAs for the 
analysis. Ethnicity was estimated by matching to surname via an al-
gorithm as previously described,14 summarising the results as either 
white British, or from an ethnic minority group. We matched cases 
to ONS death registration data for 2009- 2010 to prevent any bias 
through the censoring of late death registrations. We defined death 
as any death reported or matched in ONS data in the 28 days after 
admission to hospital.
Following the approach of an earlier analysis of the two waves of 
hospitalisations,1 we defined wave 1 as hospital admission between 
27th May 2009 and 29th August 2009, and wave 2 as admission be-
tween 30th August and 3rd January 2010. We defined “any comor-
bidity” as respiratory, renal, neurological, cardiovascular or hepatic 
disease which could impair organ function; or reported diagnosis of 
diabetes, obesity, or immunocompromised status. We also reported 
pregnancy status. To assess the timeliness of admission we excluded 
cases with onset reported after admission. Since antiviral treatment 
is most effective within 48 hours,15 we categorised antiviral use as 
within 2 days of symptom onset, or later. For analysis of the associa-
tion between antiviral use and ICU admission, we excluded patients 
who received antivirals after admission to ICU.
To account for missing values, in the primary analysis, we as-
sumed that unrecorded ICU admission or comorbidity implied the 
factor was absent since the data were collected alongside routine 
clinical care; for other variables, we excluded missing values. To ad-
dress potential bias from missing data, we conducted a secondary 
sensitivity analysis using multiple imputation, including for ICU ad-
mission and comorbidity. This method uses the distribution of the 
observed data to predict a set of credible values for the missing 
data.16 We used 20 imputed data sets, which is generally considered 
to be adequate17 and predicted missing values for the outcomes and 
exposures of interest in the primary model. If predicting variables 
were highly correlated with each other we used the most pertinent 
variable for imputation.
After comparing characteristics and case- severity between epi-
demic waves for all hospitalised patients, patients admitted to ICU, 
and patients who died in the 28 days after admission, we used lo-
gistic regression to assess which characteristics were independently 
associated with epidemic wave. We used the hierarchical approach 
proposed by Victora and others to select variables to include in mul-
tivariable models,18 adjusting first for factors such as age, gender 
and region that we considered distal to the outcomes of interest. We 
then adjusted for comorbidities, followed by proximal management 
factors— timing of admission and antiviral use.
To identify potential explanatory factors for differences be-
tween epidemic waves, we modelled predictors of ICU admission 
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and death. We then reviewed whether admission during wave 2 
predicted increased case- severity after adjusting for potential ex-
planatory factors. The study was performed in accordance with the 
NHS Act 2006 (Section 251). Data were analysed using Stata 13.1 
(StataCorp).
3  | RESULTS
Of 2380 hospitalised patients included in the analysis, 40.3% (960 
patients) were admitted during wave 1, and 59.7% (1420 patients) 
during wave 2; 36 patients were excluded because of unknown ad-
mission date. Whereas 60% of patients (n = 576) were admitted 
to hospitals in London or the West Midlands during wave 1, only 
20.1% of patients (n = 285) were admitted in these regions dur-
ing wave 2. Overall 66.5% of patients (1404/2110), patients were 
resident in areas with higher deprivation scores than the median 
level for England, including 81.2% of patients during wave 1 and 
57.1% during wave 2. Similarly, the 28.7% of patients (684/2380) 
estimated to come from ethnic minority groups represented 47.6% 
of patients during wave 1 compared with 16.0% of patients during 
wave 2.
Overall, 41.2% patients (n = 981) had an identified comorbid-
ity, including 44.4% (427/960 patients) admitted during wave 1 
and 39.0% (554/1420 patients) admitted during wave 2 (Table 1). 
Proportions of patients with specific comorbidities also varied be-
tween waves (Table 1). From wave 1 to wave 2 there were declines 
in the proportions of patients admitted with asthma from 21.9% to 
18.9%, with other respiratory disease from 7.2% to 6.5%, with neu-
rologic disease from 6.8% to 3.9%, and with diabetes from 5.7% to 
2.4%. By contrast, the proportion of patients with reported obesity 
increased from 1.7% (16 patients) during wave 1 to 2.8% (40 pa-
tients) during wave 2.
The timing of admission and antiviral use also varied between 
waves. Although the proportion of patients admitted within the 
2 days after symptom onset increased from 53.5% (461 patients) 
in wave 1 to 58.1% (802 patients) in wave 2, there was also an in-
crease in the proportion of patients admitted 4 or more days after 
illness onset, from 11.9% (103 patients) to 13.5% (186 patients). 
Meanwhile, the proportion of patients receiving antiviral therapy 
within the 2 days after symptom onset decreased from 42.1% (307 
patients) in wave 1 to 31.3% (303 patients) in wave 2.
Univariable and multivariable analyses comparing demographic, 
clinical and management characteristics between epidemic waves 
are summarised in Table 2. There was no change in gender or overall 
age distribution of patients between epidemic waves. After adjust-
ing for other characteristics, patients admitted during wave 2 were 
less likely to be resident in an area with lower socio- economic sta-
tus, have a name consistent with an ethnic minority group, or have 
asthma, diabetes or neurological disease. During wave 2, patients 
were also less likely to receive antiviral therapy in the 2 days after 
onset, and less likely to be admitted in the 4 days after illness onset 
(Table 2).
During wave 1, 54 patients (5.6%) were admitted to ICU, com-
pared with 143 patients (10.1%) during wave 2; the odds ratio for 
admission to ICU during wave 2 compared with wave 1 was 1.88 
(95% confidence interval [CI] 1.36- 2.60). Patients admitted during 
wave 2 had similarly increased odds of death within 28 days 
(1.80, CI 1.08- 3.00); there were 55 deaths (3.9% patients) during 
wave 2 compared with 21 deaths (2.2% patients) during wave 1. 
Differences in demographic, clinical and management characteris-
tics among patients who were admitted to ICU or died are sum-
marised in Table S1.
Since there was no significant evidence of interaction effects 
between wave and other covariates for the prediction of ICU and 
death, we used combined models to assess risk factors for these out-
comes (Table 2). Compared with other patients, those admitted to 
ICU had increased odds of being in the age groups 15- 44 years (OR 
3.36, CI 2.19- 5.15), or ≥45 years (OR 6.68, CI 4.29- 10.41). Patients 
who died had increased odds of being in the 15- 44 years age cat-
egory (OR 4.39, CI 1.92- 10.04) or the ≥45 years age category (OR 
13.02, CI 5.77- 29.35), and were more likely to be male (OR 1.99, 1.23- 
3.20). Patients admitted to ICU were less likely to be from an ethnic 
minority group (OR 0.61, CI 0.43- 0.87), but we did not find other 
statistical associations between ethnic group or deprivation score 
and ICU admission or death. Patients with any previous comorbid-
ity were more likely to be admitted to ICU (OR 2.28, 1.70- 3.08) or 
to die following the admission (OR 2.67, 1.66- 4.30); several specific 
comorbidities were also associated with severe outcomes (Table 2). 
Patients who died were more likely to have been admitted 4 or more 
days after symptom onset (OR 2.33, CI 1.28- 4.24). However, there 
was a weaker association between admission timing and ICU, and 
receiving antiviral therapy within 2 days after onset was not clearly 
associated with either measure of case- severity.
Multivariable models of case- severity are summarised in Table 2. 
We found that admission to ICU and death were both predicted by 
admission during wave 2, older age, neurological disease, renal dis-
ease and obesity, whereas admission with a diagnosis of asthma was 
associated with decreased odds for both outcomes. Death was also 
predicted by male gender, liver disease and immunocompromised 
status. Of factors predictive of increased case- severity, only hos-
pital admission outside London and the West Midlands and admis-
sion without asthma were statistically more likely during wave 2. 
After adjusting for other factors, patients admitted during wave 2 
remained at increased odds of ICU admission (OR 1.88, CI 1.35- 2.61) 
and death (OR 1.69, CI 1.00- 2.83).
Results were similar after using multiple imputation to estimate 
the values of missing data. Missing data are summarised in relation 
to key analysis variables in Table S2, and imputed values are given in 
Table S3. Regression analyses for differences by wave using multiple 
imputation were similar to the primary analysis, except that admis-
sion during wave 2 was not significantly associated with decreased 
odds of asthma or overall comorbidity, whereas there was a statisti-
cal increase in the proportion of patients who were pregnant during 
wave 2 (Table S4). Analyses of risk factors for ICU and death were 
also similar using multiple imputation (Table S5).
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4  | DISCUSSION
We found that from the first to second epidemic waves there was an 
approximate two- fold increase in the risk of severe outcomes of ICU 
admission and death among hospitalised patients. This is consistent 
with reports from previous studies3,9 and included an increase in 
deaths during the 28 days after hospital admission. The increased 
case- severity was accompanied by changes in populations affected, 
as well as in patient characteristics. However, we did not find that 
these reported changes could explain the observed increase in se-
verity of hospitalised cases.
As transmission shifted between waves from London and the 
West Midlands to other regions, the subgroups most affected also 
changed. We found that a substantially higher proportion of patients 
admitted during the first wave were likely to be from ethnic minority 
groups, consistent with previous studies.3,5 We also found an inde-
pendent association with increased social deprivation score— more 
than 80% of patients admitted during the first wave were living in 
area with an above- average score. However, the changes in ethnic-
ity and deprivation score could not explain increased case- severity, 
since neither attribute was associated with ICU admission or death. 
Early in the COVID- 19 pandemic, severe infections have also been as-
sociated with ethnic minority groups and patients with higher depri-
vation score.19,20 Initial evidence has suggested that, similar to our 
findings, increased mortality from COVID- 19 among ethnic minority 
groups might have initially resulted from an increased risk of trans-
mission, distinct from the risk for severe illness once hospitalised.21
Since older age is associated with ICU admission and death, a shift 
towards older ages during the second epidemic wave could theoreti-
cally explain the shift towards increased case- severity. This has been 
noted in more recent influenza seasons because of greater immu-
nity in children,22,23 and other studies of pH1N1 during 2009/2010 
found that patients were slightly older during the second wave.3- 5,24 
However, we did not find a significant shift to older ages, possibly be-
cause the two waves occurred mostly in different regions. It is unclear 
why male patients had an increased risk of death but not ICU admis-
sion in our study, but the association appears consistent with a pooled 
analysis of pH1N1 severity, as well as more recent investigation of pa-
tients with COVID- 19.19,25- 27 Nevertheless, gender could not explain 
the change in severity because it did not differ between waves.
The increased risk of severe outcomes among patients with 
comorbidities is consistent with previous studies,25 but overall co-
morbidity was reported less frequently during the second wave. Of 
specific comorbidities predictive of severe outcomes, only obesity 
was reported more frequently during the second wave— although 
this difference was not statistically significant, and obesity was only 
reported for 21 ICU admissions and 9 deaths during the second 
wave. Only hospitalisation without a diagnosis of asthma was asso-
ciated with the second wave and severe outcomes. The increased 
odds of ICU admission or death during the second wave were similar 
after adjusting for asthma diagnosis and other comorbidities, imply-
ing that none of these factors could account for the increased case- 
severity during the second wave.
Similarly, we did not find evidence that changes in patient 
management between epidemic waves led to an increase in case- 
severity. Consistent with other reports in England,2,3 we found that 
antiviral use in the 2 days after illness onset was less frequent during 
the second wave, whereas hospital admission 4 or more days after 
admission was more frequent. However, neither factor predicted 
ICU admission or death after adjustment for other characteristics, 
and the association of admission during the second wave nor in-
creased case- severity persisted after adjustment for antiviral use 
and admission timing. Vaccination is unlikely to have led to increased 
severity of hospitalised cases since it might decrease rather than 
increase case- severity, and by the end of the second wave, cover-
age remained less than 50% even in prioritised groups.2 Overall, we 
found that the increased odds of ICU admission and death during 
the second wave could not be explained by changes in any reported 
patient characteristics.
Before considering implications of our analysis, several limita-
tions should be acknowledged. A high proportion of values were 
missing for some variables. Although we did not find substantial 
differences between the primary analysis and a secondary sensi-
tivity analysis using multiple imputation, the accuracy of imputed 
values depends on an untestable assumption that values were 
“missing at random,” and predicted by other variables.16 It is also 
possible that severity changed because of changes in cases in-
cluded in surveillance. A Bayesian analysis using the same dataset 
estimated that only 30% of all hospitalisations were included in 
the first wave, and 20% in the second wave.7 Change in admis-
sion practices could also have led to increased case- severity; this 
possibility is suggested by intense media interest, higher consul-
tation rates during the first wave, and a potential tendency to 
admit milder adult cases earlier in the pandemic.9 Our finding that 
patients with asthma had milder illness and were also more likely 
to be admitted during the first wave may be consistent with this, 
although this factor alone could not explain the increase in case- 
severity. The slight increase in admissions delayed beyond 4 days 
in this study and in a previous study from sentinel surveillance3 
could also reflect decisions to admit cases perceived to be more 
severe during the second wave. Nevertheless, the increased se-
verity of hospitalised cases likely reflected a genuine increase in 
case- severity among all infections,9 and we did not find evidence 
that changes in the types of patients admitted could explain more 
severe illness during the second wave.
Our study suggests that other unrecorded factors played an im-
portant role in the increased severity of hospitalised cases. Although 
the virus itself showed no genetic changes,2 seasonal changes in 
humidity and temperature have been found to drive changes in 
transmission28 and might increase clinical severity.29 In addition, 
the winter season is associated with circulation of a range of other 
viral and bacterial respiratory pathogens, which might increase risk 
of secondary infection and hence adverse outcomes.30 Autopsies 
of cases of pH1N1 indicated an important role of bacterial coinfec-
tions during 2009/2010, including from S. pneumoniae.31 Influenza 
coinfection is associated with a substantial component of invasive 
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pneumococcal disease, which is also most frequent during winter 
months.32
This study demonstrates an increase in case- severity between 
the summer and the autumn/winter waves during the 2009 influ-
enza pandemic, highlighting the importance of real- time surveil-
lance systems to monitor severity and risk factors for severe disease 
across multiple epidemic waves. Our findings have several implica-
tions for responses to COVID- 19 as well as future influenza pandem-
ics. First, the early increase in infections among ethnic minorities 
and groups of lower socio- economic status indicates that it is im-
portant to identify demographic groups at elevated risk of infection 
to prevent further transmission and morbidity. Second, changes in 
the severity of hospitalised cases need to be monitored to support 
prioritisation of healthcare resources. Third, reasons for changes in 
severity need to be understood in order to predict changes in severe 
outcomes and to ensure that vaccines, therapeutics and other pub-
lic health interventions can be targeted most effectively. To explain 
changes in case- severity over time, surveillance systems will need to 
account for changes in thresholds for admission and seasonal factors 
such as bacterial coinfection, in addition to changes in other patient 
characteristics.
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